DEF: Cognition Therapeutics Sets 2026 Annual Meeting Date

Cognition Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026, to vote on director elections and auditor ratification.

Summary

• Cognition Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders on Wednesday, June 17, 2026, at 9:00 a.m. Eastern Time.
• The meeting will be conducted exclusively in a virtual format via the internet at www.virtualshareholdermeeting.com/CGTX2026.
• Stockholders of record as of April 20, 2026, are eligible to vote.
• The primary business of the meeting includes the election of two Class II directors, Aaron Fletcher, Ph.D. and Lisa Ricciardi, for three-year terms expiring in 2029.
• The meeting will also include the ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the 2026 fiscal year.
• Proxy materials are being made available on or about April 27, 2026.
• The company emphasizes the importance of stockholder voting, whether or not they plan to attend the virtual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily focused on procedural matters for the annual stockholder meeting, with no new financial or strategic information provided.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The virtual meeting format allows for global participation and cost savings.
• The board has nominated experienced individuals for re-election as directors.
• The company is seeking to ratify the appointment of Ernst & Young LLP, a reputable accounting firm, for the upcoming fiscal year.

Risks

• If stockholders do not ratify the appointment of Ernst & Young LLP, the Audit Committee will reconsider its selection of an alternative independent registered public accounting firm, which could lead to disruption.
• The company's insider trading policy prohibits directors and officers from various activities including trading on material non-public information, engaging in short sales, and pledging company securities, which are standard but restrictive measures.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines the agenda for the upcoming annual meeting, which includes standard corporate governance matters such as director elections and auditor ratification.

Management Comments

• "We are pleased to invite you to attend Cognition Therapeutics, Inc.s 2026 Annual Meeting of Stockholders, or the Annual Meeting, which will be held at 9:00 a.m., Eastern Time, on Wednesday , June 17, 2026."
• "We believe that the virtual meeting format enables stockholders to attend and participate from any location around the world at no cost and provides for cost savings to Cognition Therapeutics, Inc."
• "Your vote is important. Whether or not you plan to virtually attend the Annual Meeting, we hope you will vote as soon as possible."
• "Our Board is our ultimate decision-making body, except with respect to those matters reserved to the stockholders. Our Board oversees the selection of the members of our senior management team, who in turn are responsible for our day-to-day operations. Our Board acts as an advisor and counselor to senior management and oversees its performance."
• "We are committed to good corporate governance and integrity in our business dealings. We believe that strong corporate governance practices that provide meaningful rights to our stockholders and ensure Board and management accountability are key to our relationship with our stockholders."

Industry Context

StockSavvy.ai notes that holding virtual annual meetings has become a common practice in the biotechnology and pharmaceutical sectors, offering accessibility and cost efficiencies. The focus on director elections and auditor ratification is standard for publicly traded companies.

Corporate Governance

Related Party Transactions

• The filing references employment agreements with executive officers and stock option/RSU grants to NEOs and directors, which are standard compensation practices.
• Indemnification agreements are in place with directors and officers.
• A written related party transaction policy is in effect, reviewed by the Audit Committee.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification, influencing board composition and financial oversight.
• Management: Continues in their roles, with compensation details provided.
• Employees: Benefit from standard welfare and 401(k) plans, with matching contributions.
• Auditors: Ernst & Young LLP's appointment for the 2026 fiscal year is subject to ratification.

Next Steps

• Stockholders to vote on the election of directors and the ratification of the independent registered public accounting firm.
• The company will hold its 2026 Annual Meeting of Stockholders on June 17, 2026.

Key Dates

Keywords

Cognition Therapeutics, Annual Meeting, Proxy Statement, Stockholders, Directors, Ernst & Young LLP, Virtual Meeting, Corporate Governance, Voting